38186-83-3

Basic information

• Product Name: 5-Amino-2-bromo-3-methylpyridine
• Synonyms: 5-AMINO-2-BROMO-3-METHYLPYRIDINE;5-AMINO-2-BROMO-3-PICOLINE;2-bromo-3-methyl-5-aminopyridine;2-BROMO-5-AMINO-3-PICOLINE;5-AMINO-2-BROMO-3-PYRIDINE;5-AMINO-2-BROMO-3-PICOLINE (5-AMINO-2-BROMO-3-METHYLPYRIDINE);6-bromo-5-methylpyridine-3-amine;6-bromo-5-methylpyridin-3-amine
• CAS NO: 38186-83-3
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• Product Categories: Pyridine;Pyridines;Boronic Acid
• Mol File: 38186-83-3.mol
• Article Data: 1

Chemical Properties

• Melting Point: 97-100℃
• Boiling Point: 304.978 °C at 760 mmHg
• Flash Point: 138.246 °C
• Appearance: Gray/Solid
• Density: 1.593 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.02±0.20(Predicted)
• CAS DataBase Reference: 5-Amino-2-bromo-3-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-bromo-3-methylpyridine(38186-83-3)
• EPA Substance Registry System: 5-Amino-2-bromo-3-methylpyridine(38186-83-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 38186-83-3(Hazardous Substances Data)

Usage

Physical Form

5-Amino-2-bromo-3-methylpyridine is a crystal-powder at 20°C.

Uses

5-Amino-2-bromo-3-methylpyridine is a heterocyclic derivatives can be used as pharmaceutical intermediates.

InChI:InChI=1/C6H7BrN2/c1-4-2-5(8)3-9-6(4)7/h2-3H,8H2,1H3

Upstream product

• 23132-21-0 2-bromo-3-methyl-5-nitropyridine 

Downstream Products

• 96206-67-6 N-(6-bromo-5-methylpyridin-3-yl)acetamide 
• 1344734-74-2 C₃₃H₃₆FN₇O₅S 
• 1344734-67-3 C₂₄H₃₀FN₅O₄ 
• 1344734-66-2 C₂₄H₂₈FN₅O₃ 
• 1344734-65-1 C₂₃H₂₈BrFN₄O₃ 
• 1194098-48-0 C₁₂H₁₇BrN₂O 

Relevant articles and documents

Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats

A novel series of pyridyl carboxamide-based CCR5 inhibitors was designed, synthesized, and demonstrated to be highly potent against HIV-1 infection in both HOS and PBL assays. Attempts to evaluate this series of compounds in a rat PK model revealed its instability in rat plasma. A hypothesis for this liability was proposed, and strategies to overcome this issue were pursued, leading to discovery of highly potent 40 and 41, which featured dramatically improved rat PK profiles. 2011 Elsevier Ltd. All rights reserved.